



Title: Implanted Peripheral Nerve Stimulator (PNS) for Pain Control

**Professional / Institutional** 

Original Effective Date: July 1998 / December 13, 2007

Latest Revision Date: January 1, 2024 Current Effective Date: April 1, 2016

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact <u>Blue Cross and Blue Shield of Kansas Customer Service</u>.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

#### **DESCRIPTION**

The peripheral nervous system includes pathways outside of the spinal cord, specifically various plexuses and peripheral nerves. Peripherally implanted nerve stimulation entails the placement of electrodes on a selected peripheral nerve. The stimulating electrode array is connected to an implanted pulse generator.

# **POLICY**

- A. Implanted peripheral nerve stimulators may be considered **medically necessary** when **ALL** of the following criteria are met:
  - 1. Cause of pain isolated to a single nerve or in an area on a limb that can be stimulated by a proximal nerve, **AND**
  - 2. Pain is refractory to reasonable alternative therapies such as physical therapy, analgesics, anticonvulsants, muscle relaxants, antidepressants, topical anesthetics, and nerve blocks, **AND**
  - 3. Diagnosis was confirmed by nerve blocks, **AND**
  - 4. Psychological evaluation prior to trial implantation has been performed and indicates no contraindications to implantation, **AND**
  - 5. A successful trial with percutaneous leads is performed.
- B. Implanted peripheral nerve stimulators are considered **experimental / investigational** for all other indications.

Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

# CODING

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.

Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.

CPT/HC	CPT/HCPCS		
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve		
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)		
64575	Incision for implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)		
64585	Revision or removal of peripheral neurostimulator electrode array		
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver		
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array		
L8678	Electrical stimulator supplies (external) for use with implantable neurostimulator, per month		
L8680	Implantable neurostimulator electrode, each		
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only		
L8682	Implantable neurostimulator radiofrequency receiver		
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver		
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension		
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension		
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension		
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension		
L8689	External recharging system for battery (internal) for use with implantable neurostimulator, replacement only		
L8695	External recharging system for battery (external) for use with implantable neurostimulator, replacement only		

<b>REVISIONS</b>	
Effective	Description added.
11-01-2007	Policy liberalized to allow additional indications for Implanted Peripheral Nerve Stimulators.
	<ul> <li>Under item I. Conditions that may cause intractable pain, the following were deleted: Reflex sympathetic dystrophy and Causalgia" and replaced with the more current terminology and broadened application of: "Complex Regional Pain Syndrome, Type I and II" to include the definition of Complex Regional Pain Syndrome.</li> <li>Under item II, general criteria were revised to provide clarification as follows:</li> </ul>
	<ul> <li>➤ To item A. added: "by significant, function limiting pain in a peripheral nerve distribution"</li> <li>➤ To item B. added "or in an area on a limb that can be stimulated by a proximal nerve"</li> </ul>
	<ul> <li>To item C. added "such as physical therapy, analgesics, anticonvulsants, muscle relaxants, antidepressants, topical anesthetics, and nerve blocks"</li> <li>Added item F. "A successful trial with percutaneous leads is performed"</li> <li>Added item G. "Surgical decompression is not indicated"</li> <li>Added item H. "Diagnosis was confirmed by nerve blocks"</li> <li>Deleted "No nerve abnormalities demonstrable"</li> <li>Policy section revised to delete the following:         "Conditions generally NOT responsive to PNS:</li> </ul>
	<ul><li>a. Sciatica</li><li>b. Pain associated with failed low back surgery</li><li>c. Cancer pain</li></ul>
	d. Idiopathic Pain e. Pain due to nerve root injury".
01-26-2010	<ul> <li>References were updated.</li> <li>In Policy Section:</li> <li>Added clarification wording to II. E. "prior to the procedure and" so the sentence reflected, "Psychological evaluation obtained prior to the procedure and_by someone familiar with the pain process."</li> </ul>
	In Coding Section:  • Added HCPCS Codes: L8680, L8681, L8682, L8683, L8685, L8686, L8687, L8688, L8689, L8695
02-25-2011	In Coding Section: Removed CPT code 64573, 63685
01-01-2012	In Coding section: Revised CPT nomenclature for the following codes: 64553, 64555, 64575, 64585
03-13-2013	<ul> <li>In Policy section:</li> <li>Revised policy language from:</li> <li>"I. Implanted peripheral nerve stimulators may be medically necessary for the following conditions when they cause intractable pain (positive findings must be present):</li> </ul>
	A. Direct or indirect nerve trauma.  B. Complex Regional Pain Syndrome, Type I and II.  (Complex Regional Pain Syndrome [CRPS] is a chronic pain condition that is believed to be the result of dysfunction in the central or peripheral nervous systems. Typical features include dramatic changes in the color and temperature of the skin over the affected limb or body part, accompanied by intense burning pain, skin sensitivity, sweating, and swelling. CRPS Type I is frequently triggered by tissue injury; the term describes all patients with the above symptoms, but no underlying nerve injury. Patients with CRPS Type II

REVISIONS	
	experience the same symptoms, but their cases are clearly associated with a
	nerve injury.)
	II. The following general criteria may be used as a guide for review:
	A. Pathology for the pain complaint demonstrated by significant, function limiting
	pain in a peripheral nerve distribution.
	B. Cause of pain isolated to a single nerve or in an area on a limb that can be
	stimulated by a proximal nerve.
	C. Have exhausted reasonable alternative therapies such as physical therapy,
	analgesics, anticonvulsants, muscle relaxants, antidepressants, topical
	anesthetics, and nerve blocks.
	D. No serious drug habituation problems detected.
	E. Psychological evaluation obtained prior to the procedure and by someone
	familiar with the pain process.
	F. A successful trial with percutaneous leads is performed.
	G. Surgical decompression is not indicated.
	H. Diagnosis was confirmed by nerve blocks."
	In Coding section: ■ Removed CPT code 61885
	Removed diagnosis code: 723.1, 724.2
	<ul> <li>Added ICD-10 diagnoses: G90.50, G90.59, G90.511, G90.512, G90.513, G90.519,</li> </ul>
	G90.521, G90.522, G90.523, G90.529, G90.59, G56.40, G56.41, G56.42, G57.70,
	G57.71, G57.72, G89.21, G89.4, M53.1, M54.10, M54.18, M79.2, R51
	Updated Reference section.
02-10-2015	Description section updated
	In Policy Section:
	<ul> <li>In Item D removed "obtained prior to the procedure" and added "prior to trial</li> </ul>
	implantation has been performed and indicates no contraindications to implantation." to
	read "Psychological evaluation prior to trial implantation has been performed and
	indicates no contraindications to implantation."
	Other References updated
04-01-2016	In Policy section:
	<ul> <li>Added Item B, "Percutaneous tibial nerve stimulators are considered experimental /</li> </ul>
	investigational for all other indications."
	Updated References section.
10-01-2016	In Coding section:
	Added ICD-10 codes effective 10-01-2016: G56.43, G57.73
05 10 2017	Removed ICD-10 codes: G56.40, G57.70, G90.519, G90.529
05-10-2017	Policy reviewed; no changes made.
05-09-2018	In Policy section:
	In Item A, added "ALL of" to read, "Implanted peripheral nerve stimulators may be
	considered medically necessary when ALL of the following criteria are met:"  In Item A 1, added "AND" to read, "Cause of pain isolated to a single nerve or in an
	area on a limb that can be stimulated by a proximal nerve, AND"
	<ul> <li>In Item A 2, added "AND" to read, "Pain is refractory to reasonable alternative</li> </ul>
	therapies such as physical therapy, analgesics, anticonvulsants, muscle relaxants,
	antidepressants, topical anesthetics, and nerve blocks, AND,"
	<ul> <li>In Item A 3, added "AND" to read, "Diagnosis was confirmed by nerve blocks, AND"</li> </ul>
	<ul> <li>In Item A 4, added "AND" to read, "Psychological evaluation prior to trial</li> </ul>
	implantation has been performed and indicates no contraindications to implantation,
	AND"
	In Coding section:

REVISIONS		
	<ul> <li>Removed ICD-9 codes.</li> </ul>	
	Remainder of policy reviewed; no changes made.	
04-24-2019	Policy reviewed; no changes made.	
04-16-2021	Policy reviewed; no changes made.	
07-01-2022	Policy reviewed with no changes made.	
04-03-2023	Policy Section reviewed with no changes made.	
	Updated Coding Section	
	<ul> <li>Removed ICD-10 codes</li> </ul>	
	■ Added L8678	
01-01-2024	Updated Coding Section	
	<ul> <li>Updated nomenclature for 64590 and 64595 (eff. 01-01-2024)</li> </ul>	

#### **REFERENCES**

- 1. Waisbrod H, Panhans C, Hansen D, Gerbershagen H. Direct Nerve Stimulation for Painful Peripheral Neuropathies. Journ of Bone and Joint Surgery 1985; 67-B:3:470-472.
- 2. Kim P. Advanced Pain Management Techniques: An Overview of Neurostimulation. Medscape Neurology & Neurosurgery 2004; 6(1).
- 3. Slavin K, Colpan E, Munawar N, et. al. Trigeminal and Occipital Peripheral Nerve Stimulation for Craniofacial Pain: A Single-institution Experience and Review of the Literature. Neurosurgical Focus 2006; 21(6).
- 4. Goroszeniuk R, Kothari S, Hamann W. Percutaneous Implantation of a Brachial Plexus Electrode for Management of Pain Syndrome Caused by a Traction Injury. Neuromodulation: Technology at the Neural Interface 2007; 10:2:148-155.
- 5. Oh M, Oretga J, Bellotte J, et.al. Peripheral Nerve Stimulation for the Treatment of Occipital Neuralgia and Transformed Migraine Using a C1-2-3 Subcutaneous Paddle Style Electrode: A Technical Report. Neuromodulation 2004; 7:2:103-112.
- 6. Monti E. Peripheral Nerve Stimulation: A Percutaneous Minimally Invasive Approach. Neuromodulation 2004; 7:3:193-196.
- 7. Ellrich J, Lamp S. Peripheral Nerve Stimulation Inhibits Nociceptive Processing: An electrophysiological Study in Healthy Volunteers. Neuromodulation 2005; 8:4:225-232.
- 8. Johnstone C, Sundaraj R. Occipital Nerve Stimulation for the Treatment of Occipital Neuralgia Eight Case Studies. Neuromodulation 2006; 9:1:41-47
- 9. Lavano A, Volpentesta G, Piragine G, et.al. Sacral Nerve Stimulation with Percutaneous Dorsal Transforamenal Approach in Treatment of Isolated Pelvic Pain Syndromes. Neuromodulation 2006; 9:3:229-233.
- 10. Konstantin, Colpan, Munawar, et.al. Trigeminal and Occipital Peripheral Nerve Stimulation for Craniofacial Pain: A Single-Institution Experience and Review of the Literature. Neurosurg Focus 2006; 21 (6):E6:1-5.
- 11. Eisenberg, Waisbrod, and Gerbershagen. Long-Term Peripheral Nerve Stimulation for Painful Nerve Injuries. Clin J Pain, 2004; 20:3:143-146.
- 12. Schwedt, Dodick, Hentz, et.al. Occipital Nerve Stimulation for Chronic Headache--Long-Term Safety and Efficacy. Cephalalgia 2007; 27:153-157.
- 13. MCMC, Consultant, May 10, 2007, MCOP ID 1074-5165.
- 14. MCMC Consultant, August 6, 2007, MCOP ID 1075-5918.

### **OTHER REFERENCES**

- 1. Blue Cross and Blue Shield of Kansas Anesthesiology Liaison Committee, May 2007; May 2010; May 2014; May 2015, May 2021.
- 2. Blue Cross and Blue Shield Medical Advisory Committee (MAC), August 2, 2007.
- 3. Blue Cross and Blue Shield of Kansas Anesthesiology Liaison Committee CB, November 2014.